General principles of treatment of anemia in cancer patients;Principes généraux du traitement de l'anémie des patients cancéreux

Bulletin du Cancer

Volumn 89, Issue 11, 2002, Pages 935-947

  Spaeth, Dominique ^a  

^a CENTRE ALEXIS VAUTRIN   (France)

Author keywords

Anemia; Cancer; Chemotherapy; Erythropoietin; Quality of life; Radiotherapy; Transfusion

Indexed keywords

CYANOCOBALAMIN; ERYTHROPOIETIN; FOLIC ACID; NEO RECORMON; RECOMBINANT ERYTHROPOIETIN;

ALGORITHM; ANEMIA; CANCER; CANCER PATIENT; CANCER RADIOTHERAPY; FATIGUE; HUMAN; PRACTICE GUIDELINE; PROGNOSIS; QUALITY OF LIFE; REVIEW; TRANSFUSION;

ANEMIA; BLOOD TRANSFUSION; ERYTHROCYTE TRANSFUSION; ERYTHROPOIETIN; FATIGUE; HUMANS; PRACTICE GUIDELINES; QUALITY OF LIFE;

EID: 0036866311     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (136)

1. Barrett-Lee PJ, Bailey N, O'Brien MER, Wager E. Large-scale UK audit of blood transfusion requirements and anaemia in patients receiving cytotoxic chemotherapy. Br J Cancer 2000; 82: 93-7.
2. Demetri GD. Anaemia and its functional consequences in cancer patients: Current challenges in management and prospects for improving therapy. Br J Cancer 2001; 84 (suppl. 1): 31-7.
3. Glaspy JPH. Discussion. Semin Oncol 2000; 27: 16-7.
4. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: Incidence and treatment. J Natl Cancer Inst 1999; 91: 1616-34.
5. Khayat D. Is anemia a problem for European cancer patients and treating oncologists? Semin Oncol 2000; 27: 9-11.
6. Vogelzang N, Breitbart W, Cella D, Curt G, Groopman JE, Homing S, et al. Patient, caregiver, and oncologist perceptions of cancer related fatigue: Results of a tripart assessment survey. Semin Hematol 1997; 34: 4-12.
7. Practice Guideline Development Task force of American Pathologists. Practice parameter for the use of red blood cell transfusion developed by the red blood cell administration. Arch Pathol Lab Med 1998; 122: 130-8.
8. American College of Physicians. Practice strategies for elective red cell transfusion. Ann Intern Med 1992; 116: 403-6.
9. Celia D. The Functionnal Assessment of Cancer Therapy-Anemia (Fact-An) Scale: A new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 1997; 34: 13-9.
10. Yellen S, Cella DF, Webster K, Blendowski C, Kaplan E. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (Fact) measurement system. J Pain Symptom Manage 1997; 13: 63-74.
11. Demetri GD, Kris M, Wade J, Degos L, Cella D. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: Results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 1998; 16: 3412-25.
12. Gabrilove JL, Cleeland CS, Livingston RB, Soarokhan B, Winer E, Einhorn LH. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: Improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001; 19: 2875-82.
13. Glaspy J, Bukowski R, Steinberg D, Taylor C, Tchekmedyian S, Vadhan-Raj S. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol 1997; 15: 1218-34.
14. Cleeland CS, Demetri GD, Glaspy J, Cella DF, Portenoy R, Cremieux PY, et al. Identifying hemoglobin level for optimal quality of life: Results of an incremental analysis. Proc Am Soc Clin Oncol 1999; 18: 574a (abstr. 2215).
15. Nortier JWR, Zagari M, Chen Y. Marginal analysis to identify optimal hemoglobin levels to maximise quality of life improvement in anemic cancer patients receiving epoetin alfa. Ann Oncol 2000; 11: 145 (abstr. 666).
16. Marchal C. Radiothérapie et anémie. In: Spaeth D, eds. Anémie en Cancérologie. Paris, 2001 43-55.
17. Dunst J. The use of epoetin alfa to increase and maintain hemoglobin levels during radiotherapy. Semin Oncol 2001; 28: 42-8.
18. Littlewood TJ. The impact of hemoglobin levels on treatment outcomes in patients with cancer. Semin Oncol 2001; 28: 49-53.
19. Dubray B, Mosseri V, Brunin F, Jaulerry C, Poncet P, Rodriguez J, et al. Anemia is associated with lower local-regional control and survival after radiation therapy for head and neck cancer: A prospective study. Radiology 1996; 201: 553-8.
20. Wagner W, Hermann R, Hartlapp J, Esser E, Christoph B, Muller MK, et al. Prognostic value of hemoglobin concentrations in patients with advanced head and neck cancer treated with combined radio-chemotherapy and surgery. Strahlenther Onkol 2000; 176: 73-80.
21. Dumez H, Highley M, Guetens G, De Boeck G, Hanauske A, van Oosterom AT, et al. Erythrocytes and the transfer of anticancer drugs and metabolites: A possible relationship with therapeutic outcome. Semin Oncol 2001; 28: 24-8.
22. Höckel M, Vaupel P. Tumor hypoxia: Definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001; 93: 266-76.
23. Höckel M, Vaupel P. Biological consequences of tumor hypoxia. Semin Oncol 2001; 28: 36-41.
24. Sutherland RM. Tumor hypoxia and gene expression: Implications for malignant progression and therapy. Acta Oncol 1998; 37: 567-74.
25. Vaupel P, Kelleher DK, Höckel M. Oxygenation status of malignant tumors: Pathogenesis of hypoxia and significance for tumor therapy. Semin Oncol 2001; 28: 29-35.
26. Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001; 19: 2865-74.
27. Saxena S, Rabinowitz AP, Johnson C, Shulman I. Iron-deficiency anemia: A medically treatable chronic anemia as a model for tranfusion overuse. Am J Med 1993; 94: 120-4.
28. Coiffier B. The impact and management of anaemia in haematological malignancies. Med Oncol 2000; 17 (suppl. 1): S2-S10.
29. Andreu G, Benbunan M, Boasson M, Bussel A, Cordonnier C, Dosquet P. Pratiques transfusionnelles en hématologie clinique. Recommandations de la commission d'évaluation du Collège français des hématologistes pour le support transfusionnel dans le traitement des leucémies aiguës en aplasie thérapeutique. Nouv Rev Fr Hematol 1993; 35: 517-22.
30. Lassaunière J, Hunault M. Support transfusionnel et hémopathies malignes à un stade avancé. Gaz Transf 1995; 114: 53-5.
31. Anaes (Agence nationale d'accréditation et d'évaluation en santé). Indications et Contre-Indications des Transfusions de Produits Sanguins Labiles. Recommandations pour la Pratique Clinique. Paris: EDK, 1998; 156.
32. Courouce AM, Pillonel J. Transfusion-transmitted viral infections: Retrovirus and viral hepatitis working groups of the French society of blood transfusion. N Engl J Med 1996; 335: 1609-10.
33. Engert A. Recombinant human erythropoietin as an alternative to blood transfusion in cancer-related anemia. Dis Manage Health Outcomes 2000; 5: 259-72.
34. Goodnough LT, Brecher ME, Kanter MH, AuBuchon JP. Transfusion medicine. First of two parts: Blood transfusion. N Engl J Med 1999; 340: 438-47.
35. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ. The risk of transfusion-transmitted viral infections: The retrovirus epidemiology donor study. N Engl J Med 1996; 334: 1685-90.
36. Hogman C, Meryman H. Storage parameters affecting red blood cell survival and fonction after storage. Transfus Med Rev 1999; 13: 275-96.
37. Miller J, Mintz P. The use of leukocyte-reduced blood components. Hematol Oncol Clin North Am 1995; 9: 69-90.
38. Sazama K. Bacteria in blood for transfusion. Arch Pathol Lab Med 1994; 118: 350-65.
39. Andreu G, Dewailly J. Prevention of HLA alloimmunization by using leukocyte-depleted components. Curr Stud Hematol Blood Transf 1994; 60: 29-40.
40. Blumberg N, Heal JM. Effetcs of transfusion on immune function: Cancer recurrence and infection. Arch Pathol Lab Med 1994; 118: 371-9.
41. Aufeuvre J. Transfusion et cancer. Transf Clin Biol 1994; 3: 237-46.
42. Bordin J, Blajchman T. Immunosuppressive effects of allogeneic blood transfusions: Implications for the patient with a malignancy. Ann Surg 1992; 216: 633-8.
43. Blajchman M, Bardossy L, Carmen R, Sastry A, Singal D. Allogeneic blood transfusion-induced enhancement of tumor growth: Two animal models showing amelioration by leukodepletion and passive transfer using spleen cells. Blood 1993; 81: 1880-2.
44. Bordin J, Bardossy L, Blajchman M. Growth enhancement of established tumors by allogeneic blood transfusion in experimental animals and its amelioration by leukodepletion: The importance of the timing of the leukodepletion. Blood 1994; 84: 344-8.
45. Blumberg N. Allogeneic transfusion and infection: Economic and clinical implications. Semin Hematol 1997; 34 (suppl. 2): 34-40.
46. Vamvakas E, Blajchman M. Deleterious clinical effects of transfusion-associated immunomodulation: Fact or fiction? Blood 2001; 97: 1180-95.
47. Ven Der Mast B, Hornstra N, Ruigrok M, Claas F, Van Rood J, Lagaaij E. Transfusion-associated graft-versus-host disease in immuno-competents patients: A self-protective mechanism. Lancet 1994; 343: 753-7.
48. Ohto H, Yasuda H, Noguchi M, Abe, R. Risk of transfusion-associated graft-versus-host disease as a result of directed donation from relatives. Transfusion 1992; 32: 691-3.
49. Adamson JW. Epoetin alfa: Into the new millennium. Semin Oncol 1998; 25: 76-9.
50. Armitage JO. Management of anemia in patients with cancer. Clin Oncol Updates 1998; 1: 1-12.
51. Cazzola M, Mercuriali F, Brugnara C. Use of recombinant human erythropoietin outside the setting of uremia. Blood 1997; 12: 4248-67.
52. Dicato M, Duhem C, Berchem G, Ries F. Clinical benefit from erythropoietin. Curr Opin Oncol 2000; 12: 297-302.
53. Erslev AJ. Erythropoietin and anemia of cancer. Eur J Haematol 2000; 64: 353-8.
54. Gabrilove JL. New strategies and treatment modalities for optimizing patient outcomes. Semin Hematol 2001; 38: 1-7.
55. Griggs JJ, Blumberg N. Recombinant erythropoietin and blood transfusions in cancer chemotherapy-induced anemia. Anticancer Drugs 1998; 9: 925-32.
56. Kasper C, Terhaar A, Fossa A, Welt A, Seeber S, Nowrousian MR. Recombinant human erythropoietin in the treatment of cancer-related anaemia. Eur J Haematol 1997; 58: 251-6.
57. Ludwig H. Epoetin in cancer-related anaemia. Nephrol Dial Transplant 1999; 14: 85-92.
58. Ludwig H, Fritz E. Anemia in cancer patients. Semin Oncol 1998; 25: 2-6.
59. Ludwig H, Fritz E. Anemia of cancer patients: Patient selection and patient stratification for epoetin treatment. Semin Oncol 1998; 25: 35-8.
60. Mercadante S, Gebbia V, Marrazzo A, Filosto S. Anaemia in cancer: Pathophysiology and treatment. Cancer Treat Rev 2000; 26: 303-11.
61. Osterborg A. The role of recombinant human erythropoietin in the management of anaemic cancer patients: Focus on haematological malignancies. Med Oncol 2000; 17 (suppl. 1): S17-S22.
62. Osterborg A. Recombinant human erythropoietin (rHuEPO) therapy in patients with cancer-related anaemia: What have we learned? Med Oncol 1998; 15 (suppl. 1): S47-S49.
63. Quirt I, Micucci S, Moran LA, Pater J, Browman G. Erythropoietin in the management of patients with nonhematologic cancer receiving chemotherapy. Systemic Treatment Program Committee. Cancer Prev Control 1997; 1: 241-8.
64. Seidenfeld J, Piper M, Flamm C, Hasselblad V, Armitage JO, Bennett CL, et al. Epoetin treatment of anemia associated with cancer therapy: A systematic review and meta-analysis of controlled clinical trials. J Natl Cancer Inst 2001; 93: 1204-14.
65. Soignet S. Management of cancer-related anemia: Epoetin alfa and quality of life. Semin Hematol 2000; 37: 9-13.
66. Spaeth D, Marchal C, Bataillard A, Blanc-Vincent MP. Éléments de la mise à jour 1999 des Standards, Options et Recommandations pour l'utilisation de l'érythropoïétine en cancérologie. Bull Cancer 1999; 86: 631-9.
67. Spaeth D, Marchal C, Blanc-Vincent MP. Standards, options et recommandations pour l'utilisation de l'érythropoïétine en cancérologie. Bull Cancer 1998; 85: 337-46.
68. Spivak JL, Cazzola M. Current thinking and treatment practices in anaemia - An interactive poll. Med Oncol 2000; 17 (suppl. 1): S32-S37.
69. Thatcher N. Management of chemotherapy-induced anemia in solid tumors. Semin Oncol 1998; 25 (suppl. 7): 27-34.
70. Faquin WV, Schneider TJ, Goldberg MA. Effect of inflammatory cytokines on hypoxia-induced erythropoietin production. Blood 1992; 79: 1987-94.
71. Miller CB, Jones RJ, Piantadosi S, Abeloff M, Spivak JL. Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med 1990; 322: 1689-92.
72. Wood PA, Hrushesky WJ. Cisplatin-associated anemia: An erythropoietin deficiency syndrom. J Clin Invest 1995; 95: 1650-9.
73. Cascinu S, Fedeli A, Del Ferro E, Luzi Fedeli S, Catalano G. Recombinant human erythropoietin treatment in cisplatin-associated anemia: A randomized, double-blind trial with placebo. J Clin Oncol 1994; 12: 1058-62.
74. Case DCJ, Bukowski RM, Carey RW, Fishkin EH, Henry DH, Jacobson RJ. Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy. J Natl Cancer Inst 1993; 85: 801-6.
75. Dammaco F, Castoldi G, Rödger S. Efficacy of epoetin alfa in the treatment of anemia of multiple myeloma. Br J Haematol 2001; 113: 172-9.
76. Del Mastro L, Venturini M, Lionetto R, Garrone O, Melioli G, Pasquetti W, et al. Randomized phase III trial evaluating the role of erythropoietin in the prevention of chemotherapy-induced anemia. J Clin Oncol 1997; 15: 2715-21.
77. Dusenbery KE, McGuire WA, Holt PJ, Carson LF, Fowler JM, Twiggs LB. Erythropoietin increases hemoglobin during radiation therapy for cervical cancer. Int J Radiat Oncol Biol Phys 1994; 29: 1079-84.
78. Gamucci T, Thorel MF, Frasca AM, Giannarell D, Calabresi F. Erythropoietin for the prevention of anemia in neoplastic patients treated with cisplatin. Eur J Cancer 1993; 29A: S13-S14.
79. Henke M, Guttenberger R, Barke A, Pajonk F, Potter R, Frommhold H. Erythropoietin for patients undergoing radiotherapy: A pilot study. Radiother Oncol 1999; 50: 185-90.
80. Henry DH, Spivak JL. Clinical use of erythropoietin. Curr Opin Hematol 1995; 2: 118-24.
81. Kurz C, Marth C, Windbichler G, Lahousen M, Medl M, Vavra N, et al. Erythropoietin treatment under polychemotherapy in patients with gynecologic malignancies: A prospective, randomized, double-blind placebo-controlled multicenter study. Gynecol Oncol 1997; 65: 461-6.
82. Lavey RS, Dempsey WH. Erythropoietin increases hemoglobin in cancer patients during radiation therapy. Int J Radiat Oncol Biol Phys 1993; 27: 1147-52.
83. Leon PJ, Barona PSL. Recombinant human erythropoietin for the treatment of anemia in children with malignant tumors. Med Pediatr Oncol 1998; 30: 110-6.
84. Markman M, Reichmann B, Hakes T, Rubin S, Jones W, Lewis JR. The use of recombinant human erythropoietin to prevent carboplatin-induced anemia. Gynecol Oncol 1993; 49: 172-6.
85. Oberhoff C, Neri B, Amadori D, Petry KU, Gamucci T, Rebmann U, et al. Recombinant human erythropoietin in the treatment of chemotherapy-induced anemia and prevention of transfusion requirement associated with solid tumors: A randomized, controlled study. Ann Oncol 1998; 9: 255-60.
86. Porter JC, Leahey A, Polise K, Bunin G, Manno CS. Recombinant human erythropoietin reduces the need for erythrocyte and platelet transfusions in pedatric patients with sarcoma: A randomized, double-blind, placebo-controlled trial. J Pediatr 1996; 129: 656-60.
87. Quirt I, Coutere FPR, Olweny C, White D, King M. The role of Recombinant human erythropoietin (EPO) in reducing red blood cell transfusions and maintaining quality, of life (QOL) in patients with lymphoma and solid tumors receiving cytotoxic chemotherapy: Results of a randomized, double-blind, placebo-controlled trial. Blood 1996; 88: 347a.
88. Quirt I, Robeson C, Lau CY, Kovacs M, Burdette-Radoux S, Dolan S, et al. Epoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy. J Clin Oncol 2001; 19: 4126-34.
89. Silvestris F, Romito A, Fanelli P, Vacca A, Dammaco F. Long term therapy with Recombinant human erythropoietin (rHu-EPO) in progressing multiple myeloma. Ann Hematol 1995; 70: 313-8.
90. Sweeney PJ, Nicolae D, Ignacio L, Chen L, Roach M, Wara W. Effect of subcutaneous recombinant human erythropoietin in cancer patients receiving radiotherapy: Final report of a randomized, open-labelled, phase II trial. Br J Cancer 1998; 77: 1996-2002.
91. Ten Bokkel Huinink WW, de Swart CA, van Toorn DW, Morack G, Breed WP, Hillen HF, et al. Controlled multicentre study of the influence of subcutaneous recombinant human erythropoietin on anaemia and transfusion dependency in patients with ovarian carcinoma treated with platinum-based chemotherapy. Med Oncol 1998; 15: 174-82.
92. Thatcher N, De Campos ES, Bell DR, Steward WP, Varghese G, Morant R, et al. Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer. Br J Cancer 1999; 80: 396-402.
93. Varan A, Buyukpamukcu M, Kutluk T, Akyuz C. Recombinant human erythropoietin treatment for chemotherapy-related anemia in children. Pediatrics 1999; 103: E16-4.
94. Welsch RS, James R, Wilkinson PM, Belli F, Cowan RA. Recombinant human erythropoietin and platinum-based chemotherapy in advanced ovarian cancer. Cancer J Sci Am 1995; 11: 570-9.
95. Wurnig C, Windhager R, Schwameis E, Kotz RZA. Prevention of chemotherapy-induced anemia by the use of erythropoietin in patients with primary malignant bone tumors (a double-blind, randomized, phase III study). Transfusion 1996; 36: 155-9.
96. er mars 2001.
97. er mars 2001.
98. Beguin Y. Prediction of response to treatment with recombinant human erythropoietin in anaemia associated with cancer. Med Oncol 1998; 15 (suppl. 1): S38-S46.
99. Fjornes T, Wiedemann GJ, Sack K, Jelkmann W. Serum erythropoietin and creatinine concentrations as predictive factors for response to recombinant human erythropoietin treatment in anaemic tumour patients on chemotherapy. Oncol Rep 1998; 5: 81-6.
100. Cazzola M, Ponchio L, Pedrotti C, Farina G. Cerani PCL. Prediction of response to recombinant human erythtopoietin (rHuEPO) in anemia of malignancy. Haematologica 1996; 81: 434-41.
101. Osterborg A, Boogaerts MA, Cimino R, Essers U, Holowiecki J, Juliusson G, et al. Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma - A randomized multicenter study. The European Study Group of Erythropoietin (Epoetin Beta) Treatment in Multiple Myeloma and Non-Hodgkin's Lymphoma. Blood 1996; 87: 2675-82.
102. Glaus AMS. Hemoglobin and fatigue in cancer patients: Inseparable twins? Schweiz Med Wochenschr 2000; 130: 471.
103. Gleeson C, Spencer D. Blood transfusion and its benefits in palliative care. Palliat Med 1995; 9: 307-13.
104. Thomas ML. Anemia and quality of life in cancer patients: Impact of transfusion and erythropoietin. Med Oncol 1998; 15 (suppl. 1): S13-S18.
105. Leitgeb C, Pecherstorfer M, Fritz E, Ludwig H. Quality of life in chronic anemia of cancer during treatment with recombinant human erythropoietin. Cancer 1994; 73: 2535-42.
106. Mittelman M, Zeidman A, Fradin Z, Magazanik A, Lewinski UH, Cohen A. Recombinant human erythropoietin in the treatment of multiple myeloma-associated anemia. Haematologica 1997; 98: 204-10.
107. Glaspy J. The impact of epoetin alfa on quality of life during cancer chemotherapy: A fresh look at an old problem. Semin Hematol 1997; 34: 20-6.
108. Glaser CM, Millesi W, Kornek GV, Lang S, Schull B, Watzinger F, et al. Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int J Radiat Oncol Biol Phys 2001; 50: 705-15.
109. Henke M. Achievements with Recombinant Erythropoietin in Radiotherapy. John Libbey Eurotext, Paris, 2000; 57-8.
110. Antonadou D, Cardamakis E, Sarris G. Effect of the administration of recombinant human erythropoietin in patients with pelvic malignancies during radiotherapy. Radiother Oncol 1998; 48: S122 (abstr. 483).
111. Silver DF, Piver MS. Effects of recombinant human erythropoietin on the antitumor effect of cisplatin in SCID mice bearing human ovarian cancer: A possible oxygen effect. Gynecol Oncol 1999; 73: 280-4.
112. Mittelman M, Neumann D, Peled A, Kanter P, Haran-Ghera N. Erythropoietin induces tumor regression and antitumor immune responses in murine myeloma models. Proc Natl Acad Sci USA 2001; 98: 5181-6.
113. Cavill I. Does iron supplementation increase the risk of infection, bring cardiovascular complications and worsen malignant disease? Should I give intravenous iron? Why, to whom, when and how? Focus on Anemia in Cancer 2001; 2: 56.
114. Zauber N, Zauber A, Gordon F, Tillis A, Leeds H, Berman E, et al. Iron supplementation after femoral head replacement for patients with normal iron stores. JAMA 1992; 267: 525-7.
115. van Iperen C, Kraaijenhagen R, Biesma D, Beguin Y, Marx J, van de Wiel A. Iron metabolism and erythropoiesis after surgery. Br J Surg 1998; 85: 41-5.
116. Beris P. Perisurgical intravenous iron therapy. TATM 1999; 1: 35-8.
117. Singh K, Fong Y, Kuperan PA. Comparison between intravenous polymaltose complex (Fetrum Hausmann) and oral ferrous fumarate in the treatment of iron deficiency anaemia in pregnancy. Eur J Haematol 1998; 60: 119-24.
118. Selke B. Anémie: Approche Médico-économique. Livre EPO, 2001.
119. Dalton JD, Bailey NP, Barrett-Lee PJ, O'Brien MER. Multicenter UK audit of anemia in patients receiving cytotoxic chemotherapy. Proc Am Soc Clin Oncol 1998; 17: 418a (abstr. 1611).
120. Ortega A, Dranitsaris G, Puodziunas A. A clinical and economic evaluation of red blood cell transfusions in patients receiving cancer chemotherapy. Int J Technol Assess Health Care 1998; 14: 788-98.
121. Timothy A, Denton R, George A, Diamont Jack M, Matloff M, et al. Anemia therapy: Individual benefit and societal cost. Sem Oncol 1994; 21: 29-35.
122. Cremieux PY, Finkelstein SN, Berndt ER, et al. Cost effectiveness, quality-adjusted life-years and supportive care: Recombinant human erythropoietin as a treatment of cancer-associated anemia. Pharmacoeconomic. 1999; 16: 459-72.
123. Cremieux PY, Barrett B, Anderson K, Slavin MB. Cost of outpatient blood transfusion in cancer patient. J Clin Oncol 2000; 18: 2755-61.
124. Aledort LM, Mohandas K. Transfusion requirements in patients with malignancy. Semin Hematol 1996; 33 (suppl. 1): 6-9.
125. Mohandas K, Aldefort L. Transfusion requirements, risks, and costs for patients with malignancy. Transfusion 1995; 35: 427-30.
126. Sheffield RE, Sullivan SD, Saltiel E, Nishimura L. Cost comparison of recombinant human erythropoietin and blood transfusion in cancer chemotherapy-induced anemia. Ann Pharmacother 1997; 31: 15-22.
127. Barosi G, Marchetti M, Liberato NL. Cost-effectiveness of recombinant human erythropoietin in the prevention of chemotherapy-induced anaemia. Br J Cancer 1998; 78: 781-7.
128. Kavanagh BD, Fischer BAT, Segreti EM, Wheelock JB, Boardman C, Roseff SD, et al. Cost analysis of erythropoietin versus blood transfusions for cervical cancer patients receiving chemoradiotherapy. Int J Radiat Oncol Biol Phys 2001; 51: 435-41.
129. Ozer H, Armitage JO, Bennett CL, Crawford J, Demetri GD, Pizzo P, et al. 2000 Update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol 2000; 15: 3558-85.
130. Quirt I, Micucci S, Moran LA, Pater J, Browman G, and the Systemic Treatment Disease Site Group. Erythropoietin in the management of cancer patients with non-hematologic malignancies receiving chemotherapy (Practice Guideline n° 12-1). Cancer Care Ontario Practice Guideline Initiative CPG 12-1. http://hiru.mcmaster.ca/ccopgi/guidelines/sys/cpg12_1f.html. July 2000.
131. Croockewit A, Bronchud MH, Aapro MS, Bargetzi MJ, Crown J, Gratwohl A, et al. A European Perspective on Haematopoietic Growth Factors in Haemato-Oncology: Report of an Expert Meeting of the EORTC. Eur J Cancer 1997; 33: 1732-46.
132. Ray-Coquard I, Le Cesne A, Rubio MT, Mermet J, Maugard C, Ravaud A, et al. Risk modele for severe anemia requiring red blood cell transfusion after cytotoxic conventional chemotherapy regimens. J Clin Oncol 1999; 17: 2840-6.
133. Egtie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer 2001; 84: 3-10.
134. Smith RE, Jaiyesimi IA, Meza LA, Tchekmedyian NS, Chan D, Griffith H, et al. Novel erythropoiesis stimulating protein (NESP) for the treatment of anemia of chronic disease associated with cancer. Br J Cancer 2001; 84: 24-30.
135. Vanrenterghem Y, Barany P, Mann J. Novel erythropoiesis stimulating protein (NESP) maintains hemoglobin in ERSD patients when administered once weekly or once every other week. J Am Soc Nephrol 1999; 10: 270A (abstr. A1365).
136. Lamy ML, Daily EK, Brichant JF, Larbuisson RP, Demeyere RH, Vandermeersch EA, et al. Randomized trial of diaspirin cross-linked hemoglobin solution as an alternative to blood transfusion after cardiac surgery. The DCLHb Cardiac Surgery Trial Collaborative Group. Anesthesiology 2000; 92: 645-56.